Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells

Open access

Published version of a preprint

Abstract

Immunotherapy is widely accepted as a powerful new treatment modality for the treatment of cancer. The most successful form of immunotherapy to date has been the blockade of the immune checkpoints PD-1 and CTLA-4. Combining inhibitors of both PD-1 and CTLA-4 increases the proportion of patients who respond to immunotherapy. However, most patients still do not respond to checkpoint inhibitors, and prognostic biomarkers are currently lacking. Therefore, a better understanding of the mechanism by which these checkpoint inhibitors enhance antitumor immune responses is required to more accurately predict which patients are likely to respond and further enhance this treatment modality. Our current study of two mouse tumor models revealed that CD4+Foxp3− cells activated by dual PD-1/CTLA-4 blockade modulated the myeloid compartment, including activation of conventional CD103+ dendritic cells (DC) and expansion of a myeloid subset that produces TNFα and iNOS (TIP-DCs). CD4+Foxp3− T cell–mediated activation of CD103+ DCs resulted in enhanced IL12 production by these cells and IL12 enhanced the therapeutic effect of dual PD-1/CTLA-4 blockade. Given the importance of these myeloid subsets in the antitumor immune response, our data point to a previously underappreciated role of CD4+Foxp3− cells in modulating this arm of the antitumor immune response. Cancer Immunol Res; 6(9); 1069–81. ©2018 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0291

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Cited by

See all 68

Metadata

Authors
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., Mardiana, S., Slaney, C. Y., Trapani, J. A., Loi, S., Kershaw, M. H., Haynes, N. M., & Darcy, P. K.
Affiliations
The University of Melbourne (AU)
Venue
Cancer Immunology Research
Published
2018-09-01
Volume
6
Issue
9
Pages
1069-1081
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2884484117
Cited by
68
References
55
Citations by year
2026: 5 · 2025: 6 · 2024: 1 · 2023: 7 · 2022: 4 · 2021: 13 · 2020: 19 · 2019: 11 · 2018: 1
FWCI
4.13
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • Deakin Research Online (Deakin University) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
Funders
  • NHMRC (1062580)
  • Cancer Council Victoria Project Grant (APP1084420)
  • National Breast Cancer Foundation (ID# ECF-17-005 and #ECF-16-005)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
immune checkpoint inhibitors, CD4+ Foxp3+ T cells, CD103+ dendritic cells, IL-12, TNF-α, inducible nitric oxide synthase, antitumor immunity, cancer immunotherapy, prognostic factors, tumor models
MeSH terms
Animals, Dendritic Cells, Immunotherapy, Mice, Inbred C57BL, CD4-Positive T-Lymphocytes, Antigens, CD, CD8-Positive T-Lymphocytes, Interleukin-12, Integrin alpha Chains, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-gamma, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0291
The paper
Beavis, P. A., Henderson, M. A., Giuffrida, L., Davenport, A. J., Petley, E. V., House, I. G., Lai, J., Sek, K., Milenkovski, N., John, L. B., Mardiana, S., Slaney, C. Y., Trapani, J. A., Loi, S., Kershaw, M. H., Haynes, N. M., & Darcy, P. K. (2018). Dual PD-1 and CTLA-4 checkpoint blockade promotes antitumor immune responses through CD4(+)Foxp3(-) cell-mediated modulation of CD103(+) dendritic cells. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0291

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.